文献速递慢性肾脏病

从证据到实践:糖尿病肾脏病突破性疗法的实施

Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-06-01

糖尿病肾脏病是全球肾衰竭最常见病因,占全部病例的一半,1990至2013年间其死亡增加106%,多归因于心血管疾病。推荐筛查监测在不足半数糖尿病患者中开展,标准治疗ACEI或ARB使用相应偏低,SGLT2抑制剂、GLP-1受体激动剂及非甾体盐皮质激素拮抗剂高效但不足20%合格患者使用。实施障碍包括高自付药费和低报销率,需多层面协作推动可及与公平。

要点

  • 糖尿病肾脏病占全球肾衰竭病例的一半,1990至2013年死亡增加106%。
  • 推荐筛查监测在不足半数糖尿病患者中开展,ACEI或ARB标准治疗使用相应偏低。
  • SGLT2抑制剂、GLP-1受体激动剂及非甾体盐皮质激素拮抗剂高效,但不足20%合格患者使用。

核心结论

  • 糖尿病肾脏病突破性疗法的可及与实施可预防肾衰竭、心血管事件和过早死亡,从而挽救数百万生命。
  • 由患者、家庭、社区团体、卫生专业人员、卫生系统、联邦机构和支付方组成的联盟对制定协作模式以应对这一重大公共卫生挑战至关重要。

研究设计与样本

  • 本文为综述,围绕糖尿病肾脏病突破性疗法从证据到实施的障碍与策略进行论述。

主要发现

  • 糖尿病肾脏病是全球肾衰竭最常见病因,占全部病例的一半,1990至2013年间死亡增加106%,多数归因于心血管疾病。
  • 推荐筛查监测在不足半数糖尿病患者中开展,ACEI或ARB标准治疗使用相应偏低。
  • SGLT2抑制剂、GLP-1受体激动剂及非甾体盐皮质激素拮抗剂高效降低肾脏和心血管风险,但不足20%合格患者使用。
  • 关键障碍为高自付药费和低报销率;需临床与成本效果数据以争取支付方和卫生系统支持。

关键数值与推荐

  • 推荐筛查监测在不足半数糖尿病患者中开展,ACEI或ARB标准治疗使用相应偏低。
  • SGLT2抑制剂、GLP-1受体激动剂及非甾体盐皮质激素拮抗剂高效降低糖尿病肾脏病肾脏和心血管风险,但不足20%合格患者使用。

临床怎么用

  • 制药行业应通过可负担药价增加可及性,协作推进价值导向医疗。
  • 需针对各卫生系统定制多学科模式和通信技术,以支持最佳糖尿病肾脏病诊疗。
  • 社区外展对实现可及和公平的医疗至关重要。
  • 患者偏好和优先事项必须塑造实施策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic kidney disease is the most frequent cause of kidney failure, accounting for half of all cases worldwide. Moreover, deaths from diabetic kidney disease increased 106% between 1990 and 2013, with most attributed to cardiovascular disease. Recommended screening and monitoring for diabetic kidney disease are conducted in less than half of patients with diabetes. Standard-of-care treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker is correspondingly low. Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid antagonist are highly effective therapies to reduce kidney and cardiovascular risks in diabetic kidney disease. However, <20% of eligible patients are receiving these agents. Critical barriers are high out-of-pocket drug costs and low reimbursement rates. Data demonstrating clinical and cost-effectiveness of diabetic kidney disease care are needed to garner payer and health care system support. The pharmaceutical industry should collaborate on value-based care by increasing access through affordable drug prices. Additionally, multidisciplinary models and communication technologies tailored to individual health care systems are needed to support optimal diabetic kidney disease care. Community outreach efforts are also central to make care accessible and equitable. Finally, it is imperative that patient preferences and priorities shape implementation strategies. Access to care and implementation of breakthrough therapies for diabetic kidney disease can save millions of lives by preventing kidney failure, cardiovascular events, and premature death. Coalitions composed of patients, families, community groups, health care professionals, health care systems, federal agencies, and payers are essential to develop collaborative models that successfully address this major public health challenge.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Tuttle KR, Wong L, St Peter W, et al. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2022. PMID: 35649722. doi:10.2215/CJN.02980322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。